Yujiro obtained his M.B.A. at the University of Pennsylvania, his B.A. in chemistry at Colorado College, and did undergraduate studies in chemistry and biology at Oxford University. He serves on the Board of Directors at Xencor (NASDAQ: XNCR) and Expansion Therapeutics, and Board of Visitors at the Moores Cancer Center at the University of California, San Diego.
Mike obtained his B.Sc. (Hons) from the University of Leicester, and his Ph.D. in Chemistry from the University of Bristol. He completed his postdoctoral fellowship at Oregon State University to continue his research in Chemistry with Professor James D. White.
Julie completed her medical and hematology-oncology training at the University of California, San Francisco, where she then served on faculty from 1993 to 2003. She received a B.S. from Duke University, and M.D. from Case Western Reserve University School of Medicine and was Board-certified in Hematology and Internal Medicine.
He did graduate studies at Princeton and University of California at Berkeley, the later from which he received a PhD in molecular and cell biology. He was a postdoctoral fellow and staff scientist at the University of California at San Francisco and is an author of publications in Annual Review of Cancer Biology, eLife, Science, Nature Genetics, Cancer Cell, Cancer Research and Cancer Discovery.
Mark received his PhD from Stanford University in 1997 for studies on genetic analysis of RAS/MAP kinase signaling. He completed postdoctoral studies at UC Berkeley in the laboratory of Joshua Kaplan. He has authored over 55 peer reviewed scientific manuscripts in journals including Nature Medicine, Nature Communications, Journal of Clinical Oncology, Cancer Cell and Clinical Cancer Research.
Paul is a life science executive with over 20 years of legal, financial, and management experience. Paul was previously with 5AM Ventures for over nine years in various leadership capacities including as Partner, General Counsel, and Chief Operating Officer. Paul serves as a Board of Director of Scientist.Com and was a founding Director at Cidara (NASDAQ: CDTX), Homology (NASDAQ: FIXX), and IDEAYA (NASDAQ: IDYA), as well was a Board Observer at RareCyte and other companies. He also held early management and operating rolls at Cidara, Entrada, IDEAYA and Homology. Prior to joining 5AM, Paul was Senior Vice President and General Counsel at Ethos Pharmaceuticals, Senior Vice President, General Counsel and Chief Patent Counsel at Ilypsa (acquired by Amgen) and Vice President, Chief Patent Counsel at Symyx (IPO). He earlier served in roles at Boeing and Wisconsin Electric.
Paul earned a B.S. in Chemical Engineering, University of Wisconsin, Madison, after which he served as a U.S. Naval Officer on USS NIMITZ. He received a J.D. from University of Wisconsin Law School and practiced intellectual property law as a Patent Attorney at Senniger Powers. Paul taught patent law, trade secrets law and licensing as an adjunct professor at University of Missouri and Santa Clara University. He also served on the Board of Directors of a regional non-profit, Save the Bay.
Bao earned her B.S., Biochemistry, from University of California, San Diego.
Andres has 10 years of progressive accounting and finance experience for public and private life science companies. He joined IDEAYA Biosciences as Controller in August 2016 and has served as Vice President, Finance since July 2019. Prior to joining IDEAYA, Andres served as Associate Director of Financial Planning & Analysis at Pharmacyclics, Inc. (NASDAQ: PCYC), where he helped lead the organization’s finance and operations efforts in support of the successful launch of blockbuster cancer drug, IMBRUVICA® (ibrutinib). He also played a key role in building the Company’s long-range planning and the integration activities into AbbVie, following Pharmacyclics’ $21 billion acquisition. Previously, Andres held roles at Theravance, Inc. (NASDAQ: THRX) and at PricewaterhouseCoopers’ audit and assurance practice where he focused on life science and venture capital clients.
Andres obtained his B.S. in Business Administration with a concentration in Corporate Financial Management from San Jose State University and is a Certified Public Accountant, licensed in the state of California.